The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Effect of Finasteride on the Sensitivity of PSA for Detecting Prostate Cancer
Open accessAbstract
BACKGROUND: In the Prostate Cancer Prevention Trial (PCPT), men receiving finasteride had a 24.8% lower risk of prostate cancer than men receiving placebo but a higher risk of high-grade cancer. We examined the impact of finasteride on the sensitivity and area under the receiver operating characteristic curve (AUC) of prostate-specific antigen (PSA) for detecting prostate cancer. METHODS: We studied men in the placebo and finasteride groups of the PCPT who had a prostate biopsy and concurrent PSA tests during the 7-year study. We compared the placebo and finasteride groups for sensitivity and AUC of PSA for the detection of all prostate cancer, of Gleason grade 7 or higher prostate cancer, and of Gleason grade 8 or higher prostate cancer. All statistical tests were two-sided. RESULTS: Of 5112 men in the placebo group, prostate cancer was detected in 1111. Gleason tumor grade was available for 1100 men, of whom 240 had grade 7 or higher and 55 had grade 8 or higher. Of 4579 men in the finasteride group, 695 had prostate cancer. Gleason grade was available for 686 men, of whom 264 had grade 7 or higher and 81 had grade 8 or higher. The AUC of PSA for all outcomes was greater for the finasteride group than the placebo group. For detecting prostate cancer versus no cancer, the AUCs were 0.757 and 0.681, respectively (P < .001); for detecting Gleason grade > or = 7 versus < or = 6 or no cancer, the AUCs were 0.838 and 0.781, respectively (P = .003); and for detecting Gleason grade > or = 8 versus < or = 7 or no cancer, the AUCs were 0.886 and 0.824, respectively (P = .071). The sensitivity of PSA was higher for men in the finasteride group than in the placebo group at all PSA cutoffs matched by specificity. CONCLUSIONS: PSA had statistically significantly better sensitivity and AUC for detecting prostate cancer in the finasteride arm of the PCPT than in the placebo arm. This bias would be expected to contribute to greater detection of all grades of prostate cancer with finasteride.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DeLong, E. R., DeLong, D. M., & Clarke-Pearson, D. L. (1988) · Biometrics · doi:10.2307/2531595 · Cited by 22,649
The Influence of Finasteride on the Development of Prostate Cancer
Thompson, I. M., Goodman, P. J., Tangen, C. M., Lucia, M. S., Miller, G. J., Ford, L. G., Lieber, M. M., Cespedes, R. D., Atkins, J. N., Lippman, S. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030660 · Cited by 2,518
Self-citationSathianathen, N. (2021) · 50 Studies Every Urologist Should Know · doi:10.1093/med/9780190655341.003.0002 · Cited by 2,080
Pepe, M. S. (2004) · American Journal of Epidemiology · doi:10.1093/aje/kwh101 · Cited by 1,276
Thompson, I. M. (2005) · JAMA · doi:10.1001/jama.294.1.66 · Cited by 704
Self-citationRoehrborn, C. G., Boyle, P., Gould, A. L., & Waldstreicher, J. (1999) · Urology · doi:10.1016/s0090-4295(98)00655-4 · Cited by 390
Andriole, G. L., Guess, H. A., Epstein, J. I., Wise, H., Kadmon, D., Crawford, E. D., Hudson, P., Jackson, C. L., Romas, N. A., Patterson, L., et al. (1998) · Urology · doi:10.1016/s0090-4295(98)00184-8 · Cited by 202
The Prevention of Prostate Cancer — The Dilemma Continues
Scardino, P. T. (2003) · New England Journal of Medicine · doi:10.1056/nejme038109 · Cited by 149
Cited by
Prostate Specific Antigen Best Practice Statement: 2009 Update
Greene, K. L., Albertsen, P. C., Babaian, R. J., Carter, H. B., Gann, P. H., Han, M., Kuban, D. A., Sartor, A. O., Stanford, J. L., Zietman, A., et al. (2009) · Journal of Urology · doi:10.1016/j.juro.2009.07.093 · Cited by 517
Targeted proteomic strategy for clinical biomarker discovery
Schiess, R., Wollscheid, B., & Aebersold, R. (2009) · Molecular Oncology · doi:10.1016/j.molonc.2008.12.001 · Cited by 373
Long-Term Survival of Participants in the Prostate Cancer Prevention Trial
Thompson, I. M., Goodman, P. J., Tangen, C. M., Parnes, H. L., Minasian, L. M., Godley, P. A., Lucia, M. S., & Ford, L. G. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215932 · Cited by 288
Self-citationA systematic review classifies sources of bias and variation in diagnostic test accuracy studies
Whiting, P. F., Rutjes, A. W. S., Westwood, M. E., & Mallett, S. (2013) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2013.05.014 · Cited by 283
Song, Y., Tangen, C., Goodman, P., Parnes, H. L., Lucia, M. S., Thompson, I. M., & Kristal, A. R. (2008) · The Prostate · doi:10.1002/pros.20637 · Cited by 8
Self-citation
Metadata
- Authors
- Thompson, I. M., Chi, C., Ankerst, D. P., Goodman, P. J., Tangen, C. M., Lippman, S. M., Lucia, M. S., Parnes, H. L., & Coltman, C. A.
- Venue
- JNCI: Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-08-16
- Volume
- 98
- Issue
- 16
- Pages
- 1128-1133
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2160699421
- Cited by
- 323
- References
- 8
- FWCI
- 26.57
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of Finasteride on the Sensitivity of PSA for Detecting Prostate Cancer. https://app.cochat.ai/papers/10.1093/jnci/djj307
- The paper
- Thompson, I. M., Chi, C., Ankerst, D. P., Goodman, P. J., Tangen, C. M., Lippman, S. M., Lucia, M. S., Parnes, H. L., & Coltman, C. A. (2006). Effect of Finasteride on the Sensitivity of PSA for Detecting Prostate Cancer. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djj307
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
